Answers are grounded in this paper and cite their sources.
Enfortumab vedotin is a novel treatment for metastatic urothelial carcinoma. In 2019, the United States Food and Drug Administration approved the drug as a third-line treatment for patients who had failed in previous trials of programmed cell death protein 1 and platinum-based chemotherapeutic agents.1 The drug has demonstrated to have a significant response rate in early phase trials and is known for its tolerable side-effect profile.2 The adverse effects of enfortumab vedotin include fatigue, peripheral neuropathy, alopecia, and rash.
No takes yet. Share an insight, caveat, or question.
Francis et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: